Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Smith & Nephew Snats ( (SNN) ) has issued an update.
Smith & Nephew reported first-quarter 2026 revenue of $1,501 million, up 3.1% on an underlying basis and 6.6% on a reported basis, aided by a foreign exchange tailwind and despite one fewer trading day versus 2025. Growth was broad-based across business units and regions, with Sports Medicine delivering strong gains, Advanced Wound Management posting modest underlying growth, and anticipated softness in U.S. knee implants and Chinese ENT sales reflecting portfolio and regulatory dynamics.
More than half of the group’s growth came from products launched in the past five years, with platforms such as REGENETEN, CATALYSTEM, AETOS, FASTSEAL and LEAF delivering double-digit increases and reinforcing Smith & Nephew’s innovation-led strategy. Management reaffirmed its full-year 2026 guidance, signaling confidence that revenue growth will skew to the second half on the back of new product ramp-ups, stabilizing U.S. skin substitutes and an improving U.S. knees trajectory, and announced a new $500 million share buyback, underscoring robust free cash flow and a commitment to returning capital to shareholders.
The integration of recently acquired Integrity Orthopaedics, including its Tendon Seam technology, is progressing as planned and strengthens the company’s leading shoulder portfolio. Meanwhile, the RISE strategy is gaining early traction through expanded clinical evidence, targeted investments in wound care expansion for PICO, and proactive management of China’s evolving volume-based procurement regime, positioning Smith & Nephew to balance growth opportunities with regulatory and competitive pressures.
The most recent analyst rating on (SNN) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a global medical technology company specializing in orthopaedics, sports medicine, ear, nose and throat (ENT) devices, and advanced wound management solutions. Its portfolio includes joint repair implants, arthroscopic enabling technologies, bioactive wound products and negative pressure devices, with a growing emphasis on innovation-led platforms such as REGENETEN and PICO targeting surgical and chronic care markets worldwide.
The company’s Sports Medicine business has now surpassed Orthopaedic Reconstruction and Robotics in size, reflecting a strategic shift toward faster-growing soft tissue and minimally invasive segments. Smith & Nephew continues to expand through targeted acquisitions like Integrity Orthopaedics, while leveraging its strong balance sheet to invest in product launches and return capital to shareholders through buybacks.
Average Trading Volume: 923,191
Technical Sentiment Signal: Hold
Current Market Cap: $13.24B
Find detailed analytics on SNN stock on TipRanks’ Stock Analysis page.